The European Medicines Agency (EMA) has initiated a rolling review for biotech company Valneva's Covid-19 vaccine candidate, the EMA announces in a news release.
This means that Valneva can submit data in smaller chunks, instead of having to deliver a full data package to the EMA, cutting down on case processing overall.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.